Continuing Pharmacy Education / CE Master List / Ayahuasca and Drug Interaction: The Good, the Bad, the Soul-RECORDED WEBINAR
Please use this button to register in our system as a new user, or to purchase a CE Activity.
For free CE's, returning users can simply click the "TAKE TEST/EVALUATION" button on the right.
Please use this button when you have completed the CE Activity and are ready to take the quiz and complete the evaluation.

Ayahuasca and Drug Interaction: The Good, the Bad, the Soul-RECORDED WEBINAR

The Arthur E. Schwarting Symposium is an educational conference focused on pharmacy practice for pharmacists in many settings.

This year's sympoisum had an overall topic of Drug Induced Disease from a Patient Safety perspective.  This presentation deals with secondary cancers resulting from primary cancer treatment.

Learning Objectives

The activity met the following learning objectives for Pharmacists:
·  Describe pharmacological properties of harmala alkaloids in ayahuasca
·  Define adverse reactions associated with food and dietary interactions with ayahuasca such as hypertensive crisis and serotonin toxicity
·  Construct management strategies to avoid adverse reactions from interacting foods and drugs
·  Discuss observational, clinical, and toxicologic studies relating to ayahuasca use

Activity Release Dates

Released:  April 27, 2023
Expires:  April 27, 2026

Course Fee

$17 Pharmacist

ACPE UAN Codes

 0009-0000-23-009-H05-P

Session Code

23RW09-ABC28

Accreditation Hours

1.0 hours of CE

Accreditation Statement

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive 1.0 CE Hour  for completing the activity  (ACPE UAN 0009-0000-23-009-H05-P), passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

Grant Funding

There is no grant funding for this activity.

Faculty

Benjamin Malcolm, PharmD., MPH
Psychopharmacology Consultant
Spirit Pharmacist LLC
Eugene OR

Faculty Disclosure

  • Benjamin Malcolm is both an owner and employee of Spirit Pharmacist LLC. He plays an advisor role in exchange for stock in the non-publicly traded company Kaivalya Kollectiv. He functions as a psychopharmacology consultant and has existing financial relationships with several retreat center organizations. He does not own any stock or company that aims to develop pharmaceutical or supplement products.

 

Disclaimer

The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

Content

Post Test Pharmacist

Which of the following is true about harmala alkaloid inhibition of MAO?

  1. Harmalas strongly inhibit both MAO-A and MAO-B
  2. Harmalas are irreversible inhibitors of MAO-A
  3. Harmalas are reversible inhibitors of MAO-A

 

Which of the following is/are red flags for serotonin toxicity when using psychedelics?

  1. Fever > 101F
  2. Dilated pupils
  3. Hallucination

 

Which of the following drugs do you predict to be dangerous with MAOIs?

  1. A drug that releases serotonin
  2. A drug that increases GABA neurotransmission
  3. A drug that binds to opioid receptors

 

A new drug named Seratanin has come to market. You research this compound and find that it works by blocking serotonin reuptake, lacks active metabolites, and has an elimination half life of ~48 hours. Which of the following do you predict?

  1. It could be dangerous with ayahuasca if not avoided for at least 10 days prior
  2. It could be dangerous with ayahuasca if not avoided at least 48 hours prior
  3. It could be dangerous with ayahuasca if not avoided at least 6 days prior

 

Why is it difficult to analyze calls made to poison control centers concerning Ayahuasca?

  1. Poison control centers have received fewer than 100 calls since they started tracking so any assumption lacks statistical significance
  2. Poison control centers have been unable to verify contents of ayahuasca or other concurrent drugs users were taking
  3. Most of the calls come from older women, reflecting the Baby Boomers propensity to be more accepting of hallucinogens